Replies to post #408 on Humacyte Inc (HUMA)

[threebabiesbusy]

I’m a LT holder…..
D. Boral Capital says the selloff in shares of Humacyte (HUMA) following the company’s $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte’s financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels “poised to revolutionize vascular trauma,” D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25